<div id="readability-page-1"><ul><li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li></ul><p>AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals,  and Cencora are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies whose primary business involves using biological processes and organisms to develop products such as new drugs, therapies, diagnostics, or agricultural solutions. Investors in biotech stocks gain exposure to the potential high rewards—and high risks—associated with breakthroughs in areas like gene editing, monoclonal antibodies, and personalized medicine. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><ul><li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li></ul><p>NYSE:ABBV traded up $2.91 during mid-day trading on Friday, hitting $188.49. 3,117,385 shares of the company traded hands, compared to its average volume of 6,095,522. The firm has a market cap of $333.43 billion, a price-to-earnings ratio of 78.54, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The stock's fifty day moving average price is $194.70 and its 200-day moving average price is $187.26. AbbVie has a one year low of $153.58 and a one year high of $218.66. </p><p>Read Our Latest Research Report on ABBV</p><h2>Thermo Fisher Scientific (TMO)</h2><ul><li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li></ul><p>Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.</p><p>NYSE TMO traded down $4.44 on Friday, hitting $406.34. 946,980 shares of the stock were exchanged, compared to its average volume of 1,791,243. The firm has a market capitalization of $153.39 billion, a P/E ratio of 24.58, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific has a 52-week low of $402.81 and a 52-week high of $627.88. The stock has a fifty day moving average price of $466.94 and a two-hundred day moving average price of $516.54. </p><p>Read Our Latest Research Report on TMO</p><h2>Danaher (DHR)</h2><p>Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.</p><p>Danaher stock traded down $2.64 during trading hours on Friday, reaching $192.18. The stock had a trading volume of 1,798,261 shares, compared to its average volume of 3,386,028. Danaher has a 52 week low of $171.00 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a market cap of $137.54 billion, a price-to-earnings ratio of 36.40, a PEG ratio of 2.66 and a beta of 0.80. The business's 50 day moving average price is $198.72 and its 200-day moving average price is $219.95. </p><p>Read Our Latest Research Report on DHR</p><h2>Vertex Pharmaceuticals (VRTX)</h2><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p><p>Shares of VRTX traded up $4.28 during mid-day trading on Friday, reaching $433.88. The company had a trading volume of 666,263 shares, compared to its average volume of 1,383,221. The stock has a 50 day moving average of $489.96 and a two-hundred day moving average of $466.24. The stock has a market capitalization of $111.54 billion, a P/E ratio of -197.22, a PEG ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. </p><p>Read Our Latest Research Report on VRTX</p><h2>Cencora (COR)</h2><p>Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p><p>Cencora stock traded up $3.71 during midday trading on Friday, reaching $287.48. The company had a trading volume of 932,783 shares, compared to its average volume of 1,514,605. The firm's fifty day simple moving average is $275.89 and its 200-day simple moving average is $252.97. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company has a market capitalization of $55.75 billion, a P/E ratio of 40.89, a P/E/G ratio of 1.31 and a beta of 0.60. Cencora has a 12-month low of $214.77 and a 12-month high of $309.35. </p><p>Read Our Latest Research Report on COR</p><h2>Read More</h2><ul><li>MarketBeat's Top Five Stocks to Own in May 2025</li><li>Google Is Betting Big on Nuclear Reactors—Should You?</li><li>Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs</li><li>Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings</li><li>Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend</li><li>What the ExtraHop Deal Means for CrowdStrike</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

VRTX

<p>MarketBeat's stock screener highlights five biotech stocks to watch: AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and Cencora. These companies are noted for their significant trading volumes and potential in drug development and therapies. AbbVie, with a market cap of $333.43 billion, trades at $188.49. Thermo Fisher Scientific has a market cap of $153.39 billion, trading at $406.34. Danaher, valued at $137.54 billion, trades at $192.18. Vertex focuses on cystic fibrosis treatments, showcasing the diverse opportunities in the biotech sector.</p>

Best Biotech Stocks To Keep An Eye On - May 9th